Enlivex Therapeutics shares surge 77.31% premarket on positive six-month Allocetra trial data and $212M PIPE financing.

Enlivex Therapeutics surged 77.31% in premarket trading following two key announcements: (1) a $212 million private investment in public equity (PIPE) at a 11.5% premium to fund its RAIN prediction-markets token treasury strategy, and (2) positive six-month Phase IIa trial results for Allocetra™ in knee osteoarthritis, demonstrating durable pain reduction and functional improvement with a favorable safety profile. The PIPE, priced at $1.00 per share, signals strong investor confidence in the company’s capital-raising and strategic initiatives, while the clinical data reinforce Allocetra™’s therapeutic potential and support plans for a Phase IIb trial in 2026. Both events collectively drove the sharp premarket rally, highlighting advancements in product development and financial flexibility.